DDW Highlights: 2 June 2026

The Oxford Vaccine Group (OVG) has mobilized a rapid‑response effort to manufacture its Bundibugyo Ebola candidate, CHADOX1‑BDBV, in partnership with the Clinical Biomanufacturing Facility and the Serum Institute of India. Leveraging the CHADOX viral‑vector platform that powered the AstraZeneca COVID‑19 vaccine, OVG aims to deliver scalable doses for the current Bundibugyo outbreak in the Democratic Republic of Congo. The collaboration underscores how pre‑existing platform expertise and global manufacturing networks can compress timelines from years to months, a model increasingly vital for emerging infectious disease preparedness.

Verve Therapeutics’ in‑vivo gene‑editing drug Verve 102 demonstrated a single‑dose LDL‑cholesterol reduction of roughly 62% in the Heart 2 study, prompting FDA Fast‑Track designation for hyperlipidaemia patients at high cardiovascular risk. By permanently silencing the PCSK9 gene in the liver, the therapy could replace lifelong statin regimens with one‑time treatment, potentially reshaping cardiovascular care. In parallel, researchers at Christiana Care identified an eight‑gene HOX signature that reliably predicts poor survival in colorectal cancer, offering a new biomarker for risk stratification and a possible target for combination therapies that restore developmental signaling balance. New pre‑clinical work suggests that oral mucosal stem cells can infiltrate mouse brain tissue, slowing glioblastoma growth and amplifying the effect of standard chemotherapy without damaging healthy cells.

Meanwhile, a Texas A M team is engineering synthetic peptide shuttles capable of traversing the blood‑brain barrier to deliver therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative disorders. By exploiting endogenous transport pathways and integrating AI‑driven peptide design, the approach promises to overcome a long‑standing delivery obstacle. These innovative strategies illustrate how drug‑discovery pipelines are expanding beyond traditional small molecules toward biologics and precision delivery platforms.